Cancer cells don't announce themselves in blood
For generations, the blood draw has served as medicine's most accessible window into the body's hidden life — and now researchers are asking whether it might also become a window into cancer's earliest stirrings. The answer, as of today, is a cautious not yet: blood tests can raise suspicion, track known disease, and illuminate certain cancers of the blood itself, but they cannot yet stand alone as a reliable diagnosis for most solid tumors. What is emerging, through the study of circulating tumor DNA and other molecular traces cancer leaves behind, is a science still in formation — promising enough to sustain serious effort, humble enough to resist premature certainty.
- The gap between what patients hope blood tests can do and what they can actually deliver remains wide — most cancers still require biopsies or imaging to confirm what a blood draw can only suggest.
- Tumor markers like prostate-specific antigen can flag a problem, but infections, inflammation, and even exercise can mimic the same signals, forcing doctors into rounds of additional testing before any conclusion is safe.
- Circulating tumor cells offer a way to monitor cancer already in progress, but they typically appear only after disease has spread — arriving too late to fulfill the promise of early detection.
- Circulating tumor DNA is now the most active frontier, with 2025 trials tracking hundreds of patients across colon and lung cancers, and one test claiming to detect over fifty cancer types — though expert skepticism about real-world performance persists.
- The field is advancing in measured steps: each trial adds a piece, each new marker narrows the uncertainty, and the trajectory points toward a future diagnostic tool that does not yet exist but grows less hypothetical each year.
When a doctor orders a blood test after unexplained weight loss or persistent fatigue, patients often wonder whether it might catch something serious — cancer, perhaps, before it has a chance to spread. The honest answer is that blood tests are not there yet. They can hint, they can flag, they can raise concern. But hints are not diagnoses, and for most cancers, confirmation still requires a biopsy or imaging scan.
Blood cancers are the clearest exception. Leukemia and lymphoma alter the body's cell production in ways that show up directly in a complete blood count — abnormal quantities of white or red cells that signal something has gone wrong. Even so, elevated white cell counts can reflect infection or inflammation, and additional testing is almost always required before a conclusion is reached.
For solid tumors, researchers have long relied on tumor markers — proteins that cancer cells overproduce and release into the bloodstream. Prostate-specific antigen is the most familiar example, a protein that rises sharply in many prostate cancer patients. The problem is that it also rises in response to inflammation or injury, making it a signal that demands interpretation rather than a verdict on its own.
A different approach tracks cancer cells that have broken away from a tumor and entered the bloodstream. These circulating tumor cells are useful for monitoring patients already in treatment, but they tend to appear only after cancer has advanced — too late to serve the goal of early detection.
The most promising current direction is circulating tumor DNA: fragments of genetic material shed by cancer cells, carrying mutations that distinguish them from healthy DNA. In 2025, Australian researchers used this method to predict which colon cancer patients would respond to chemotherapy, while a separate trial followed nearly a thousand lung cancer patients through treatment. One test called Galleri claimed to detect more than fifty early-stage cancer types using this approach, though some experts have questioned whether its real-world performance matches its claims.
Researchers are also finding that certain fats in the blood may predict treatment response in advanced prostate cancer, and that existing tests can be adapted to detect ovarian cancer markers from blood rather than tissue. The progress is real but incremental. A single, reliable, universal cancer detection test remains years away — but the science is moving steadily in that direction, guided by a clearer understanding of what cancer, even in its earliest stages, leaves behind.
Your doctor notices you've lost weight without trying, or you mention feeling persistently tired. The natural next step is a blood test—a straightforward procedure that has become the workhorse of modern medicine. Blood work can reveal infections, track organ function, measure glucose levels, assess nutritional status. It's reliable, it's routine, and it's often the first window into what's happening inside the body. But there's a question that haunts both patients and researchers: can blood tests do what we most want them to do—catch cancer early, before it spreads?
The short answer is no, not yet. Blood tests cannot reliably diagnose most cancers on their own. The fundamental problem is one of distinction. Cancer cells and healthy cells can look deceptively similar under scrutiny, especially when a tumor is still small. A blood test might hint that something is wrong, but hints are not diagnoses. They are starting points that demand confirmation through biopsies, imaging scans, or other invasive procedures. This limitation has not stopped researchers from pursuing the possibility, though. What they've discovered is that blood can tell us things about cancer—just not everything, and not always clearly.
Blood cancers are the exception. When leukemia or lymphoma develops, the body produces abnormal quantities of blood cells, and these changes show up unmistakably in a complete blood count. A test that tallies red cells, white cells, and platelets can reveal when something has gone wrong with the body's cell-production machinery. But even then, a high white cell count doesn't automatically mean cancer. Infection, inflammation, or other conditions can cause the same elevation. Confirmation requires additional testing—a biopsy, perhaps, or imaging to rule out other explanations.
For solid tumors, researchers have turned to tumor markers—proteins that cancer cells produce in abnormally high quantities. Prostate-specific antigen is the classic example. A healthy man's prostate releases only small amounts of this protein into the bloodstream. A man with prostate cancer often produces far more. The protein becomes a flag, a signal worth investigating. Yet here too, the signal is imperfect. An inflamed prostate, an injury, even vigorous exercise can elevate these markers. A doctor seeing a high reading must dig deeper, order more tests, before concluding that cancer is present.
Another approach tracks circulating tumor cells—cancer cells that have broken free from the original tumor and entered the bloodstream. But this method has a critical limitation: these cells typically appear only when cancer has already advanced and begun to spread. Finding them is useful for monitoring a patient whose cancer is already known, for watching how treatment is working. It is not useful for early detection, which is where blood tests could make their greatest impact.
The frontier now is circulating tumor DNA. These are fragments of genetic material shed by cancer cells, carrying mutations that distinguish them from healthy DNA. In 2025, Australian researchers used circulating tumor DNA to predict which colon cancer patients would respond to chemotherapy, studying 441 people. Another 2025 trial tracked 940 lung cancer patients, using the same approach to monitor treatment response. One test, called Galleri, claimed to detect more than fifty types of early-stage cancer using this method. It was first trialed in the UK in 2021, but some experts have since questioned whether the test performs as advertised.
Researchers are also exploring unconventional markers. A 2025 Australian study adapted an existing test to use blood samples instead of tissue to identify ovarian cancer markers. Another found that certain fats circulating in the blood can predict whether a patient with advanced prostate cancer will respond to treatment. The work is incremental, the progress real but measured. No single blood test has emerged that can reliably catch most cancers early and alone. The dream of a universal cancer detector—a simple draw, a quick result, a diagnosis—remains out of reach. But the direction of research is clear. With time, with more trials, with the accumulation of knowledge about what cancer cells leave behind in the bloodstream, that dream may eventually become possible.
Notable Quotes
It's often difficult to distinguish between cancer cells and normal, healthy cells, especially when it comes to early-stage tumors— Research findings on cancer detection limitations
A single blood test solution for cancer detection remains elusive, though researchers are making progress with circulating tumor DNA and other emerging approaches— Current state of cancer detection research
The Hearth Conversation Another angle on the story
Why is it so hard to spot cancer in blood if cancer cells are actually in the bloodstream?
Because cancer cells don't announce themselves. Early on, there might be just a handful of them swimming among billions of normal cells. The blood test has to distinguish the abnormal from the normal, and at that scale, it's like finding a specific grain of sand on a beach.
So tumor markers—those proteins cancer produces—why aren't they the answer?
They would be, except cancer cells aren't the only things that produce them. An inflamed prostate raises the same marker as prostate cancer. A blood test sees the elevation but can't tell you why it's there. You need other tests to confirm.
What about this circulating tumor DNA everyone's talking about?
That's the real hope. Cancer cells leave behind fragments of their own mutated DNA in the blood. It's like finding a fingerprint that belongs only to cancer. The problem is we're still learning how to read those fingerprints reliably, especially when the cancer is small.
The Galleri test claimed to detect fifty types of cancer. Why the skepticism?
Because claiming something and proving it are different things. Early results looked promising, but when other researchers looked closer, the picture got more complicated. Some cancers it caught well, others not so much. It's a reminder that one test rarely solves everything.
So how far away are we from a real answer?
Years, probably. Maybe a decade. The research in 2025 shows we're on the right track—we understand more about what cancer leaves in the blood. But we're still building the tools to read those signals clearly and early enough to matter.